Autolus Therapeutics plc 8-K

What Happened

• Autolus Therapeutics plc announced that its Audit Committee dismissed Ernst & Young LLP (UK) as the Company’s independent registered public accounting firm on April 14, 2026. The company filed a Current Report on Form 8‑K dated April 16, 2026 and included a letter from EY UK dated April 16, 2026 as an exhibit.

Key Details

• Dismissal date: April 14, 2026; Form 8‑K filed April 16, 2026.
• EY UK audited the consolidated financial statements for fiscal years ended December 31, 2025 and December 31, 2024; those audit reports were unmodified (no adverse opinion, disclaimer, or qualification).
• During the two most recent fiscal years (2024 and 2025) there were no “disagreements” or “reportable events” with EY UK, except the Company had previously disclosed (in its Form 10‑Q for the quarter ended March 31, 2024) that its internal control over financial reporting was not effective due to material weaknesses as of March 31, 2024.
• The Company provided EY UK with a copy of this Form 8‑K and requested a letter from EY for filing with the SEC.

Why It Matters

• A change in independent auditor is a material corporate governance event that investors watch because it can affect financial reporting continuity and audit oversight.
• This filing confirms there were no unresolved disagreements with EY UK about accounting or auditing matters for the covered periods and that prior audit opinions were unmodified, which mitigates immediate concerns about past financial statements.
• Investors should monitor subsequent disclosures for the identity of any new auditor, any transition-related timing or costs, and any updates about the Company’s internal control remediation efforts.